Extended Data Table 1 Selected baseline and demographic characteristics in all treated patients and candidate biomarker-evaluable populations

From: Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial